Association Between HER2 Status and pCR Rate in ER-positive Breast Cancer Receiving Neoadjuvant Endocrine or Chemotherapy

Peking University

Status

Completed

Conditions

Breast Neoplasms

Treatments

Drug: NET or NCT

Study type

Observational

Funder types

Other

Identifiers

NCT05673850

ASSOCIHER

Details and patient eligibility

About

In estrogen receptor (ER)-positive breast cancer (BC), human epidermal growth factor receptor-2 (HER2)-low ones are reported to have distinct clinical and molecular features from those with HER2-zero or HER2-positive status. However, the association between HER2-low status with response to endocrine therapy is largely unknown. In this study, we included 518 ER-positive BC patients who received either neoadjuvant endocrine therapy (NET) or neoadjuvant chemotherapy (NCT). The pathologic complete response rate (pCR) of HER2-low and HER2-zero tumors re-sponding to neoadjuvant therapies were compared. The difference in disease-free survival (DFS) and overall survival (OS) between the two groups was also analyzed. The pCR (defined as ypT0/isNx) in HER2-low BCs and in HER2-zero BCs for NET cohort and NCT cohort were compared.

Enrollment

518 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

patients diagnosed with invasive breast cancer and who received surgery from 2015 to 2021

Exclusion criteria

none